相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
Len Neckers et al.
CELL STRESS & CHAPERONES (2018)
Combination Therapies Targeting HDAC and IKK in Solid Tumors
Ivana Vancurova et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Angela Nebbioso et al.
CLINICAL CANCER RESEARCH (2017)
Histone Deacetylase (HDAC) Inhibition Induces IkB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells
Himavanth R. Gatla et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer
Richard J. Rebello et al.
GENES (2017)
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study
Manish K. Thakur et al.
INVESTIGATIONAL NEW DRUGS (2016)
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors
Pradeep S. Jadhavar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Yang Hai et al.
NATURE CHEMICAL BIOLOGY (2016)
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
Julia Hoefer et al.
ONCOTARGET (2016)
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells
Rayna Rosati et al.
MOLECULAR PHARMACOLOGY (2016)
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma
Dong-Yeop Shin et al.
CANCER LETTERS (2015)
NF-kappa B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Nagalakshmi Nadiminty et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
T. Hideshima et al.
BLOOD CANCER JOURNAL (2015)
Androgen receptor: structure, role in prostate cancer and drug discovery
M. H. Eileen Tan et al.
ACTA PHARMACOLOGICA SINICA (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials
Dharam Kaushik et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas
Roberta Zappasodi et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Berkley E. Gryder et al.
ACS CHEMICAL BIOLOGY (2013)
Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression
Guan-Min Jiang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
Dana E. Rathkopf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades
CANCER RESEARCH (2013)
RNAi-Mediated Silencing of Myc Transcription Inhibits Stem-like Cell Maintenance and Tumorigenicity in Prostate Cancer
Gianluca Civenni et al.
CANCER RESEARCH (2013)
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer
Joseph Ischia et al.
CURRENT OPINION IN UROLOGY (2013)
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
Benjamin E. L. Lauffer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Synthesis and Structure-Activity Relationship Studies of Novel Dihydropyridones as Androgen Receptor Modulators
Antonella Pepe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90
Russell R. A. Kitson et al.
NATURE CHEMISTRY (2013)
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Lina Gao et al.
PLOS ONE (2013)
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
Ayesha A. Shafi et al.
STEROIDS (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
Berkley E. Gryder et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
Dejuan Kong et al.
PLOS ONE (2012)
Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
Changmeng Cai et al.
CANCER CELL (2011)
Estrogen-Initiated Transformation of Prostate Epithelium Derived from Normal Human Prostate Stem-Progenitor Cells
Wen-Yang Hu et al.
ENDOCRINOLOGY (2011)
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc
Caihua Zhu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
Yixian Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Michael E. Jung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Derek S. Welsbie et al.
CANCER RESEARCH (2009)
Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer
Maulik R. Shah et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer
Junkui Ai et al.
MOLECULAR ENDOCRINOLOGY (2009)
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6
Angela Gibbs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Intratumor injection of the hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
Christopher R. Williams et al.
JOURNAL OF UROLOGY (2007)
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Paola Gallinari et al.
CELL RESEARCH (2007)
Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity
KP De Jesus-Tran et al.
PROTEIN SCIENCE (2006)
The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain -: RU-486 induces a transconformation that leads to active antagonism
B Kauppi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists
VS Wilson et al.
TOXICOLOGICAL SCIENCES (2002)
分享论文
